ACG has announced a $200m phased investment to establish its first empty-capsule manufacturing operations in the United States.
The initial $100m will fund a state-of-the-art hard-shell capsule facility in Atlanta, Georgia, with a second phase of $100m planned to expand capacity and capabilities in the region.
The investment is expected to create more than 200 jobs, with operations targeted to begin in early 2027.
"ACG has served North America for more than 25 years," said Karan Singh, Managing Director, ACG.
"This facility strengthens our ties with customers across the region — bringing us closer to them, enabling faster lead times, higher-quality service and a more resilient, de-risked supply chain."
"Just as importantly, it lets us respond more quickly and co-develop new innovations through tighter R&D partnerships."
ACG will establish dedicated facilities to manufacture gelatine and vegetarian (HPMC) hard-shell capsules, designed and operated to the highest global standards of quality, safety and regulatory compliance.
The programme advances ACG's Make it Better commitment and complements the company's US ecosystem spanning capsules, barrier packaging materials, processing and encapsulation machinery, visual inspection and traceability solutions—supported by nationwide sales and service.
"Atlanta is the right location to execute at scale," said Selwyn Noronha, CEO, ACG Capsules.
"Georgia and the City of Atlanta offer a pro-business environment, a strong talent pipeline, world-class connectivity and reliable infrastructure."
"Combined with ACG's recent facility builds in Aurangabad (HPMC), Thailand (gelatine) and expansions in Brazil, Croatia and India, we have the operating discipline to begin production quickly and deliver reliable supply for North American customers."
